Difference between revisions of "Doxepine-maprotiline"
From Psychiatrienet
| Line 3: | Line 3: | ||
| to = maprotiline | | to = maprotiline | ||
| stop = | | stop = | ||
| − | + | {{downDoxepin}} | |
| − | |||
| start = | | start = | ||
* No wash-out period is needed. | * No wash-out period is needed. | ||
| − | * | + | * ''' Day 9: ''' start administration of maprotiline in a normal dosage of 25-75 mg/day. |
| − | |||
| − | |||
| − | |||
}} | }} | ||
Revision as of 13:37, 2 November 2015
| ||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||
Switch medication from doxepin to maprotiline.[2] [3]
Stop doxepin - Before day 1: gradually reduce dosage of doxepin to a maximum of 100 mg/day.
- Day 1: reduce dosage of doxepin to 50 mg/day.
- Day 3: reduce dosage of doxepin to 25 mg/day.
- Day 8: stop administration of doxepin.
Start maprotiline- No wash-out period is needed.
- Day 9: start administration of maprotiline in a normal dosage of 25-75 mg/day.
- ↑ 1.0 1.1 1.2 1.3 1.4 KNMP; Informatorium Medicamentorum 2023; Monografie "doxepine" (Dutch)
- ↑ Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
- ↑ Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.
